Full Name
Jill Goldstein
Job Title
Principal
Company
Vida Ventures
Speaker Bio
Jill Goldstein, Ph.D., is a Principal at Vida Ventures. She has deep expertise in genetic medicines and focuses broadly across multiple therapeutic areas, including oncology, rare disease, and immunology.
Jill has worked as a Board Director or Observer for several Vida portfolio companies, including Volastra Tx, Soufflé Tx, Halda Tx (acquired by J&J), Tectonic Tx (NASDAQ: TECX), and Affini-T Tx.
Prior to joining Vida full-time, Jill was a Fellow in the Vida Ventures Fellowship Program. Jill was a Postdoctoral Fellow at Harvard University in the Department of Stem Cell and Regenerative Biology focusing on gene and cell therapy for blood and muscle diseases as well as in vivo gene editing. She earned a Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University with a focus on stem cell biology as well as a B.S. in Biochemistry and German Studies with high distinction from Worcester Polytechnic Institute. Jill has authored over 10 scientific publications and is a co-inventor on three patents.
Jill has worked as a Board Director or Observer for several Vida portfolio companies, including Volastra Tx, Soufflé Tx, Halda Tx (acquired by J&J), Tectonic Tx (NASDAQ: TECX), and Affini-T Tx.
Prior to joining Vida full-time, Jill was a Fellow in the Vida Ventures Fellowship Program. Jill was a Postdoctoral Fellow at Harvard University in the Department of Stem Cell and Regenerative Biology focusing on gene and cell therapy for blood and muscle diseases as well as in vivo gene editing. She earned a Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University with a focus on stem cell biology as well as a B.S. in Biochemistry and German Studies with high distinction from Worcester Polytechnic Institute. Jill has authored over 10 scientific publications and is a co-inventor on three patents.
